Niacin: the evidence, clinical use, and future directions. - Wikidata - awgldk - TriplyDB

Niacin: the evidence, clinical use, and future directions.

Niacin: the evidence, clinical use, and future directions.

http://www.wikidata.org/entity/Q34228636

about

Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.Consensus statement on management of dyslipidemia in Indian subjects.Nicotinuric acid: a potential marker of metabolic syndrome through a metabolomics-based approach.Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization.Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.Clinical relevance of target identity and biology: implications for drug discovery and development.Metabolic syndrome and polycystic ovary syndrome: an intriguing overlapping.Plaque imaging to refine indications for emerging lipid-lowering drugs.Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.A modified method for studying behavioral paradox of antioxidants and their disproportionate competitive kinetic effect to scavenge the peroxyl radical formation

P2860

Q26771862-73558E0D-72E4-455B-86D0-285DB789EB3B Q34712851-A996B677-138B-4882-98E4-612E0ED2E75B Q34980772-6C33C242-7C13-433C-B215-F64028B0D9A8 Q36868136-E3668CC4-C0A1-4439-8583-619DB9B0649B Q37635019-9128A4FB-5CCF-4704-9762-6BA4AF760572 Q38092792-ECBF8459-E152-41CB-AC07-3E0C62A10570 Q38147723-3EC24B19-537D-47A2-82DE-D057492FE7EF Q38189473-A75944AC-0EF2-4F37-8FBE-F3BA4D7FE5B6 Q39000038-B583387A-C1CC-42EE-9A93-F0FCAE567DD3 Q48311790-76D4B9B7-C92B-4DED-8051-5B11571E900B Q59101318-38411B1B-5FF8-4633-9F06-F0A46BEA8951

P2860

Niacin: the evidence, clinical use, and future directions.

http://www.wikidata.org/entity/Q34228636

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Niacin: the evidence, clinical use, and future directions.

@ast

Niacin: the evidence, clinical use, and future directions.

@en

Niacin: the evidence, clinical use, and future directions.

@nl

type

label

Niacin: the evidence, clinical use, and future directions.

@ast

Niacin: the evidence, clinical use, and future directions.

@en

Niacin: the evidence, clinical use, and future directions.

@nl

prefLabel

Niacin: the evidence, clinical use, and future directions.

@ast

Niacin: the evidence, clinical use, and future directions.

@en

Niacin: the evidence, clinical use, and future directions.

@nl

P1433

Q34228636-9F4B0A34-9686-48CF-B42C-502E141743A3

P1476

Q34228636-E455F90E-A55F-474F-9AD2-53D52A0AFE70

P2093

Q34228636-887F0D1D-D3AE-4A42-AD35-219BAE402F80

Q34228636-9111F46D-E0B7-412C-8836-9EEEADC39105

Q34228636-9D8F3135-0A09-4189-A5C9-6D453F540D42

P2860

Q34228636-096E0128-8BFD-441C-9119-78D75CFC8027

Q34228636-09EB9934-75A4-4FAD-92DF-EDFB308281BA

Q34228636-0FF4E32A-08BE-4C53-BD8B-7D41FCB28B12

Q34228636-10A6436D-73D6-480E-AB99-F2097A593CE9

Q34228636-125DCFC8-4996-495C-A457-4B313C0CD201

Q34228636-1407DF63-BADD-4B72-AA4C-7D93C83CF365

Q34228636-1B0C267F-AFD7-447C-991E-5FFAC72CC96C

Q34228636-1CDC8134-11A6-4263-BD33-FD54E54F07E9

Q34228636-1E0A118B-7F73-4714-9F91-F4997378C8BC

Q34228636-258A88B4-7E4A-4E9F-B479-404A6F4AAF29

P2888

Q34228636-5D66EDDA-AF87-4E9E-840D-3C39DBB27706

P304

Q34228636-D9DD89C0-5206-4A0D-8670-505936F81770

P31

Q34228636-D886CA14-BD63-47A3-A34B-DD6468A5205E

P356

Q34228636-F77CBD32-B14C-4E3E-9835-9571ABF7F2F0

P433

Q34228636-52CC42EC-39B1-483B-8A31-1A2D1A53AFE8

P478

Q34228636-AFDB9C59-C177-4F8D-BDFA-0639F8705D77

P50

Q34228636-FCE3039C-20D3-4386-B73A-1A39664DEEE2

P577

Q34228636-45EC33DD-A000-4B65-8150-2E95A549AFBE

P6179

Q34228636-A00CAA19-A530-44E6-97BD-EC69FEB1E41D

P698

Q34228636-6510DB2F-3F69-4A69-B06E-B2119A19D82F

P356

S11883-011-0212-1

P1433

Current Atherosclerosis Reports

P1476

Niacin: the evidence, clinical use, and future directions

@en

P2093

Allen J Taylor

http://www.w3.org/2001/XMLSchema#string

Andrew S Kim

http://www.w3.org/2001/XMLSchema#string

Rosco S Gore

http://www.w3.org/2001/XMLSchema#string

P2860

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin

Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment

Nicotinic acid: pharmacological effects and mechanisms of action

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.

Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Athero

P2888

s11883-011-0212-1

P304

49-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11883-011-0212-1

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Todd C Villines

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1049237920

http://www.w3.org/2001/XMLSchema#string

P698

22037771

http://www.w3.org/2001/XMLSchema#string